Pre-clinical studies consistently demonstrated favourable chondroprotective and immunomodulatory effects of GLP-1A in osteoarthritis, with a dose-dependent effect, primarily driven by inhibition of NF-κB pathway. Here, NFKB1 is linked to osteoarthritis.